Findings by a team of researchers suggest that levels of circulating endothelial cells and fibrocytes may be used as predictive biomarkers in idiopathic pulmonary fibrosis (IPF). The team’s study, “Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments,” was published in the journal…
Potential IPF Disease Biomarkers Seen in Patients’ Blood
Esbriet (pirfenidone, Genentech) is an anti-fibrotic drug developed as a therapy for pulmonary fibrosis (PF), and was the first drug to receive approval for PF treatment in the United States. New data on Esbriet was recently presented by Dr. Steven Nathan, Medical Director, Advanced Lung Disease…
https://www.youtube.com/watch?v=CfmkE6zqT9A “Dolores has Idiopathic Pulmonary Fibrosis (IPF) and tells her story about living with lung disease. Dolores found help in dealing with her illness by contacting the Irish Lung Fibrosis Association (ILA).” Learn more about IPF: https://bit.ly/1XjPFMa…
1. Esbriet’s Promise and Potential as a PF Therapy 2. IPF Experts Discuss Disease Diagnosis and Treatment at CHEST 2015 3. Boehringer Ingelheim’s OFEV (Nintedanib) IPF Therapy Reinforces Efficacy and Safety Profile in New Studies …
The Pulmonary Fibrosis Foundation (PFF) recently announced that it has acquired the Daughters of Pulmonary Fibrosis program from the Coalition for Pulmonary Fibrosis (CPF), a 501c(3) nonprofit organization based in California that serves the pulmonary fibrosis (PF) community. By assuming the administration of the Daughters of PF program and giving money raised…
Cotrimoxazole (Trisulfa-FPI) is a combination of trimethoprim and sulfamethoxazole in fixed amounts (trimethoprim 80 mg and sulfamethoxazole 400 mg) used to treat bacterial, fungal and protozoal infections. It is developed and marketed worldwide with different brand names including Septra (GlaxoSmithKline plc) and Bactrim (Hoffmann-La Roche). Being a broad…
miRagen Therapeutics, Inc., a biopharmaceutical company dedicated to the development of pioneering therapies based on microRNAs, recently announced the start of a Phase 1 clinical trial on the company’s product MRG-201 developed as a therapy for fibrotic conditions. MicroRNAs (miRNAs) are small RNAs that act as master regulators of…
“Patients, caregivers, and physicians discuss the disease and the role the Pulmonary Fibrosis Foundation has played in the past years.” Learn more about Pulmonary Fibrosis Foundation: https://bit.ly/1MkiSzf …
Evel Knievel was an American daredevil, entertainer, and international icon. He attempted more than 75 ramp-to-ramp motorcycle jumps between 1965 and 1980, and in 1974, a canyon jump across Snake River Canyon (which failed) in a team-powered rocket. During his career, he suffered more than 433 bone fractures, which gave…
aTyr Pharma Inc., a biotherapeutics company that discovers and develops medicines through its Physiocrine platform for the treatment of rare diseases, has announced the selection of a new Investigational New Drug (IND) candidate, an iMod.Fc molecule. The selected therapeutic molecule aims to aid in the management of severe fibrotic…
